<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721978</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-303</org_study_id>
    <nct_id>NCT03721978</nct_id>
  </id_info>
  <brief_title>REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)</brief_title>
  <official_title>Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HPV-303 is a prospective, randomized, double-blind, placebo-controlled phase 3 study of
      VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with
      CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous
      intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3
      [CIN3]) of the cervix, associated with HPV-16 and/or HPV-18.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of cervical HSIL on histology as well as evidence of HPV-16 and/or HPV-18 in cervical samples by type-specific HPV testing at the Week 36 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants with Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Investigational Treatment and for the Duration of the Study</measure>
    <time_frame>From baseline to Week 40</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. An SAE is any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of Cervical HSIL at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of cervical HSIL on histology at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of HPV-16 and/or HPV-18 in Cervical Samples at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of HPV-16 and/or HPV-18 in cervical samples by type-specific HPV testing at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of Low Grade Squamous Intraepithelial Lesion (LSIL) or HSIL at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of cervical LSIL and HSIL (i.e. no evidence of cervical intraepithelial neoplasia grade 1 [CIN1], CIN2 or CIN3) on histology at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18 at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of cervical LSIL and HSIL (i.e. no evidence of CIN1, CIN2 or CIN3) on histology and be evaluated for evidence of HPV-16 and/or HPV-18 in cervical samples by type-specific HPV testing at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Progression of Cervical HSIL to Cervical Carcinoma from Baseline at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for progression of cervical HSIL to cervical carcinoma from baseline on histology at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for HPV-16 and/or HPV-18 status in specimens from non-cervical anatomic locations (oropharynx, vagina and intra-anal) at the Week 36 Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations at Weeks 15 and 36</measure>
    <time_frame>At Weeks 15 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma Response Magnitudes at Baseline, Weeks 15 and 36</measure>
    <time_frame>At Baseline, Weeks 15 and 36</time_frame>
    <description>Interferon-gamma response magnitudes will be determined using the ELISpot assay at baseline, Weeks 15 and 36 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune Response Magnitudes at Baseline and Week 15</measure>
    <time_frame>At Baseline and Week 15</time_frame>
    <description>Using flow cytometry cellular immune response magnitudes will be determined at the baseline and Week 15 visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Cervical Dysplasia</condition>
  <condition>Cervical High Grade Squamous Intraepithelial Lesion</condition>
  <condition>HSIL</condition>
  <arm_group>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + EP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VGX-3100</intervention_name>
    <description>1 milliLiter (mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.</description>
    <arm_group_label>Placebo + EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CELLECTRA™-5PSP</intervention_name>
    <description>CELLECTRA™-5PSP is used for EP following IM injection of VGX 3100 or placebo on Day 0, Week 4 and Week 12.</description>
    <arm_group_label>Placebo + EP</arm_group_label>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 years and above

          -  Confirmed cervical infection with HPV types 16 and/or 18 at screening

          -  Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for
             diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first
             dose of study drug

          -  Confirmed histologic evidence of cervical HSIL at screening

          -  Must be judged by Investigator to be an appropriate candidate for the
             protocol-specified procedure required at Week 36

          -  With respect to their reproductive capacity must be post-menopausal or surgically
             sterile or willing to use a contraceptive method with failure rate of less than 1% per
             year when used consistently and correctly from screening until Week 36

          -  Normal screening electrocardiogram (ECG)

        Exclusion Criteria:

          -  Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar,
             vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic
             specimen at screening

          -  Cervical lesion(s) that cannot be fully visualized on colposcopy

          -  History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or
             insufficient for diagnosis

          -  Treatment for cervical HSIL within 4 weeks prior to screening

          -  Pregnant, breastfeeding or considering becoming pregnant during the study

          -  History of previous therapeutic HPV vaccination

          -  Immunosuppression as a result of underlying illness or treatment

          -  Receipt of any non-study, non-live vaccine within 2 weeks of Day 0

          -  Receipt of any non-study, live vaccine within 4 weeks of Day 0

          -  Current or history of clinically significant, medically unstable disease or condition
             which, in the judgment of the investigator, would jeopardize the safety of the
             participant, interfere with study assessments or endpoint evaluation, or otherwise
             impact the validity of the study results

          -  Presence of acute or chronic bleeding or clotting disorder that would contraindicate
             IM injections, or use of blood thinners within 2 weeks of Day 0

          -  Participation in an interventional study with an investigational compound or device
             within 30 days of signing informed consent

          -  Less than two acceptable sites available for IM injection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Bhuyan, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inovio Call Center</last_name>
    <phone>267-440-4237</phone>
    <email>clinical.trials@inovio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Visions Clinical Research- Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Nichele Bonnett</last_name>
      <phone>520-546-4700</phone>
      <email>nlpollock@visionstucson.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Holly Defeo</last_name>
      <phone>203-739-4860</phone>
      <email>holly.defeo@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Dr. Chuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Denise DeMaio, BSN, RN</last_name>
      <phone>302-623-4639</phone>
      <email>denise.a.demaio@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Dr. Borowsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Ixsa Morel</last_name>
      <phone>561-641-0404</phone>
      <phone_ext>105</phone_ext>
      <email>imorel@altusresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Lederman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salom and Tangir LLC</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Back-Up Study Coordinator Stephanie Paguada</last_name>
      <phone>954-602-9723</phone>
      <email>student1@salomtangir.org</email>
    </contact>
    <investigator>
      <last_name>Dr. Black</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Jessica Moo-Young</last_name>
      <phone>954-915-9991</phone>
      <email>jessicam@pcrflorida.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research Institute</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Sheela Shrestha</last_name>
      <phone>630-491-1908</phone>
      <email>sheela.shrestha@acri-research.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Rana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praetorian Pharmaceutical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Lyza Murillo, CRC</last_name>
      <phone>504-934-8093</phone>
      <email>lyza@praetorianpharmaceutical.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Nicholson-Uhl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Hagerstown</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Melissa Sexton, CRC</last_name>
      <phone>301-665-9098</phone>
      <phone_ext>337</phone_ext>
      <email>melissa.sexton@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group LLC</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Jaclyn Muter</last_name>
      <phone>989-497-5851</phone>
      <email>jmuter@womensob.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Minnec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Pamela Chandler</last_name>
      <phone>402-371-0797</phone>
      <email>pchandler@mcrmed.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Vrbicky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10583</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Reena Vattakalam</last_name>
      <phone>212-342-6895</phone>
      <email>rmv2110@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Tergas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suffolk Obstetrics and Gynecology</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Catherine Sigismondi</last_name>
      <phone>631-656-4060</phone>
      <email>csigismondi@prohealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Greensboro</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Jessica Nikki, CRC</last_name>
      <phone>336-544-3327</phone>
      <email>jessica.gaudioso@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Morehead City</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Amie Butler</last_name>
      <phone>336-354-1076</phone>
      <email>amie.butler@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Parker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinOhio Research Services</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Jim Sanders, MPH</last_name>
      <phone>614-668-6630</phone>
      <email>jsanders@clinohioresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Associates, Inc.</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Alecia Corcoran</last_name>
      <phone>513-878-1003</phone>
      <email>alecia.corcoran@elligodirect.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Bonar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Julie Black, MA, CRC</last_name>
      <phone>724-569-8100</phone>
      <phone_ext>3</phone_ext>
      <email>jblack@frontierclinical.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Hojat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Venus Gynecology, LLC</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Amy Miller</last_name>
      <phone>843-449-0803</phone>
      <email>amym@magnoliaobgyn.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Kirkpatrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Physician Group Suite 203</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Shanta Williams</last_name>
      <phone>901-276-3222</phone>
      <email>swilliams@wccmemphis.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Carter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Storks Research</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Lilly Buckins</last_name>
      <phone>281-942-7171</phone>
      <email>lilly@storksresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Group For Women - Tidewater Clinical Research Inc.</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator April Rusch</last_name>
      <phone>757-471-3375</phone>
      <email>tcrrusch@cox.net</email>
    </contact>
    <investigator>
      <last_name>Dr. Parva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecología</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000PBB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Gabriela Santillan</last_name>
      <phone>﻿﻿+543414475116</phone>
      <email>gabriela@ginecologiarosario.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Riegé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Mariela Prada</last_name>
      <phone>﻿﻿+541149590200</phone>
      <phone_ext>8675</phone_ext>
      <email>mariela.prada@hospitalitaliano.org.ar</email>
    </contact>
    <investigator>
      <last_name>Dr. Velazco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DIM Clinica Privada</name>
      <address>
        <city>Ramos Mejía</city>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator Gloria Cendali</last_name>
      <phone>﻿﻿+541146562828</phone>
      <email>gloriacndali@clinicadim.com.ar</email>
    </contact>
    <investigator>
      <last_name>Dr. Casadei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associação Obras Sociais Irmã Dulce Hospital Santo Antônio</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40420-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas de Goiânia</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74605-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho</name>
      <address>
        <city>Jaú</city>
        <state>São Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Adriana dos Santos</last_name>
      <phone>﻿﻿+551436021397</phone>
      <email>centrodepesquisas.adrianasantos@amaralcarvalho.org.br</email>
    </contact>
    <investigator>
      <last_name>Dr. Beato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Michelle Silveira</last_name>
      <phone>﻿﻿+551636025257</phone>
      <email>mcsmurari@hcrp.usp.br</email>
    </contact>
    <investigator>
      <last_name>Dr. Quintana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pärnu Hospital</name>
      <address>
        <city>Pärnu</city>
        <state>Pärnumaa</state>
        <zip>EE-80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Kadri-Liina Vahula, MD</last_name>
      <phone>﻿﻿+3724473500</phone>
      <email>kadri-liina.vahula@ph.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital Womens Clinic</name>
      <address>
        <city>Tallinn</city>
        <zip>10119</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Pille Aavik</last_name>
      <phone>﻿﻿+3726516199</phone>
      <email>pille.aavik@itk.ee</email>
    </contact>
    <investigator>
      <last_name>Dr. Aavik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Terje Raud, MD</last_name>
      <phone>﻿﻿+3727319993</phone>
      <email>terje.raud@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius District Central Outpatient Clinic</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-01117</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Justina Bikaite</last_name>
      <phone>﻿﻿+37062612899</phone>
      <email>justlandija@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Teiberiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Tadas Zvirblis</last_name>
      <phone>﻿﻿+37060422106</phone>
      <email>tadas.zvirblis@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Dr. Rudaitis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Translational Research Center (PRTRC)</name>
      <address>
        <city>Rio Piedras</city>
        <zip>﻿00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Janice Diaz Monge</last_name>
      <phone>(787) 759-0306</phone>
      <phone_ext>221</phone_ext>
      <email>janice.diaz2@upr.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Mendez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynette Reynders Private Practice</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>﻿0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Hestelle Roux</last_name>
      <phone>﻿﻿+27126640261</phone>
      <email>hgraaff@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Reynders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>﻿08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Elena Fabra</last_name>
      <phone>﻿﻿+34932607695</phone>
      <phone_ext>2976</phone_ext>
      <email>efabra@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Dr. Fernandez Montoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Victoria Bravo</last_name>
      <phone>﻿﻿+34913908376</phone>
      <email>vitobv@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. López González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Estonia</country>
    <country>Lithuania</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hpvreveal2.com/</url>
    <description>Study Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical intraepithelial neoplasia (CIN)</keyword>
  <keyword>CIN 2</keyword>
  <keyword>CIN 3</keyword>
  <keyword>Human papillomavirus (HPV)</keyword>
  <keyword>HPV-16</keyword>
  <keyword>HPV-18</keyword>
  <keyword>High Grade Squamous Intraepithelial Lesion (HSIL)</keyword>
  <keyword>papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

